High-risk localized prostate cancer is a highly heterogeneous disease from a clinical and biological standpoint. It carries a significant chance of morbidity and mortality. The 2015 National Comprehensive Cancer Network (NCCN) guidelines define high-risk prostate cancer as a biopsy Gleason score of 8–10, a PSA level greater than 20 ng/mL, or clinical stage T3a disease. Despite the impact of PSA screening on improves outcome of men with prostate cancer, a significant proportion of men continue to present with high risk disease and need optimal treatment.
Published August 15, 2017